Patients with advanced pancreatic cancer who had already failed at least one round of chemotherapy lived roughly twice as long when treated with a once-daily oral pill called daraxonrasib, according to results from a 500-person phase 3 trial. Median overall survival reached 13.2 months with the drug compared to 6.7 months with standard chemotherapy, and the hazard ratio of 0.40 signaled a 60 percent reduction in the risk of death. Revolution Medicines disclosed the findings ahead of an ASCO plenary presentation, marking one of the largest survival gains ever reported in second-line pancreatic cancer.
Why doubling survival in second-line pancreatic cancer changes the calculus
Pancreatic ductal adenocarcinoma kills most patients within a year of diagnosis, and options after first-line treatment fails have historically added only weeks of life. The standard second-line regimens, typically nanoliposomal irinotecan-based combinations or single-agent gemcitabine, produce median survival figures clustered around six to seven months. Against that baseline, a hazard ratio of 0.40 with P less than 0.001 represents a statistical signal strong enough to force regulatory and clinical reassessment of how second-line therapy is chosen.
The trial, formally titled RASolute 302, enrolled patients with previously treated metastatic pancreatic ductal adenocarcinoma and randomized them to daraxonrasib or investigator’s choice of standard-of-care chemotherapy. The trial registration describes an open-label, multicenter design in which physicians selected the best available chemotherapy regimen for each patient in the control arm, effectively raising the bar for the experimental drug. Daraxonrasib still cleared it by a wide margin.
A practical question follows immediately: if an oral RAS inhibitor can produce 13.2-month median survival in the second-line setting, what happens when it is tested against FOLFIRINOX or gemcitabine plus nab-paclitaxel as initial treatment? Those frontline regimens currently deliver median survival of roughly 11 to 13 months in metastatic disease. Should daraxonrasib show a comparable hazard ratio in first-line trials, the gap between frontline and salvage therapy could narrow sharply, potentially reshaping treatment sequencing within a few years.
Trial design and the NEJM data behind the 0.40 hazard ratio
The primary evidence comes from a peer-reviewed abstract published in the New England Journal of Medicine. In the overall population, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy. In a prespecified RAS G12 population, the numbers were nearly identical: 13.2 months versus 6.6 months. Both comparisons carried a hazard ratio of 0.40 with a P value below 0.001, meaning the probability that the survival difference arose by chance was less than one in a thousand.
Daraxonrasib, also known by its development code RMC-6236, is a multi-RAS inhibitor designed to block the signaling cascade that drives tumor growth in cancers carrying RAS mutations. More than 90 percent of pancreatic cancers harbor KRAS mutations, which historically made them resistant to targeted therapy. The drug is taken orally once a day, replacing the intravenous infusions and clinic visits that chemotherapy demands. For patients already weakened by prior treatment, that difference in administration alone carries real quality-of-life weight.
Revolution Medicines described the survival benefit as “unprecedented” in its plenary announcement, which previewed the 13.2-month median overall survival and the 0.40 hazard ratio. The company scheduled a formal presentation of the full dataset at the American Society of Clinical Oncology annual meeting, where the data will face scrutiny from independent oncologists and biostatisticians.
What the RASolute 302 results do not yet answer
Several gaps in the public record limit how far conclusions can be drawn. The NEJM abstract and ClinicalTrials.gov listing do not yet detail the full breakdown of patient demographics, stratification factors, or the exact enrollment count beyond the approximate 500-person figure referenced in the headline claim. Knowing how patients were distributed by age, performance status, prior regimen, and geographic region matters because pancreatic cancer outcomes vary significantly across these variables.
Safety data also remain incomplete in the public domain. Grade 3 and grade 4 adverse event rates, dose reductions, and treatment discontinuation numbers have appeared only in summary form. Until the full manuscript and supplementary tables are published, clinicians cannot weigh the survival benefit against the toxicity profile in granular detail. An oral drug taken daily for months raises distinct tolerability questions compared to time-limited infusion cycles.
Another unknown is how daraxonrasib performs in specific molecular subsets beyond the RAS G12 group highlighted in the abstract. Pancreatic tumors often carry co-mutations in genes such as TP53, CDKN2A, or SMAD4, which can influence both prognosis and drug sensitivity. Without more detailed molecular correlative analyses, it is difficult to identify which patients derive the most benefit or whether certain subgroups respond less robustly.
Questions also remain about resistance. Targeted therapies that inhibit oncogenic signaling pathways frequently produce initial tumor shrinkage followed by progression as cancer cells adapt. The current data focus on overall survival and, to a lesser extent, progression-free survival, but they do not yet outline the mechanisms by which tumors escape RAS inhibition or how quickly resistance emerges in the majority of patients. That information will be crucial for designing rational combination regimens.
Implications for regulators and clinical practice
Despite the gaps, the magnitude of benefit reported in RASolute 302 is likely to draw close attention from regulators. A randomized phase 3 trial demonstrating a doubling of median overall survival in a setting with few effective options typically meets the bar for full approval, assuming the safety profile proves manageable. Agencies will, however, want to see complete data on adverse events, quality of life, and consistency of benefit across prespecified subgroups.
For clinicians, the trial raises immediate practical questions. If daraxonrasib becomes available, it could supplant current second-line standards for patients with RAS-mutant tumors, which represent the vast majority of pancreatic ductal adenocarcinoma cases. Oncologists would need to reconsider how aggressively they push first-line regimens such as FOLFIRINOX, knowing that a potent, better-tolerated oral option exists for later lines. Shared decision-making conversations with patients may shift toward preserving performance status to remain eligible for daraxonrasib.
Payers and health systems will also have to grapple with cost and access. Oral targeted therapies often carry high list prices, and the durability of benefit with daraxonrasib-how long patients remain on therapy before progression-will influence budget impact calculations. If the survival advantage proves as strong in real-world practice as in the trial, pressure to provide broad coverage will be intense, particularly given the historically poor outcomes in this disease.
What comes next for daraxonrasib and RAS targeting
The logical next steps include testing daraxonrasib earlier in the treatment course and in combination with other agents. Moving the drug into first-line metastatic pancreatic cancer could determine whether RAS inhibition can outperform or at least match the best existing chemotherapy regimens. Combination strategies might pair daraxonrasib with chemotherapy, immune checkpoint inhibitors, or agents targeting downstream nodes in the RAS pathway to delay or overcome resistance.
Beyond pancreatic cancer, the trial may reinvigorate efforts to target RAS mutations across tumor types. Success in a malignancy as refractory as pancreatic ductal adenocarcinoma suggests that multi-RAS inhibition can deliver clinically meaningful benefit where more selective approaches have struggled. However, confirming that promise will require similarly rigorous, randomized data in other cancers, along with careful monitoring for on-target toxicities in normal tissues that depend on RAS signaling.
For now, the RASolute 302 results mark a rare moment of optimism in a field long defined by incremental gains. If the full dataset presented at ASCO and subsequently published matches the early signals, daraxonrasib could represent a genuine shift in the standard of care for patients whose disease has already defied one line of therapy. The coming months, and the detailed data they bring, will determine whether this early promise translates into a durable new chapter in pancreatic cancer treatment.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
